Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Research & Development (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Research & Development for 16 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 29.71% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, up 13.92% year-over-year, with the annual reading at $13.7 million for FY2025, 13.92% up from the prior year.
  • Research & Development for Q4 2025 was $4.8 million at Gyre Therapeutics, up from $2.4 million in the prior quarter.
  • The five-year high for Research & Development was $20.4 million in Q3 2021, with the low at -$50.2 million in Q4 2021.
  • Average Research & Development over 5 years is $2.9 million, with a median of $3.4 million recorded in 2024.
  • The sharpest move saw Research & Development crashed 96.05% in 2022, then soared 274.72% in 2023.
  • Over 5 years, Research & Development stood at -$50.2 million in 2021, then soared by 108.59% to $4.3 million in 2022, then grew by 6.01% to $4.6 million in 2023, then fell by 18.74% to $3.7 million in 2024, then increased by 29.71% to $4.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $4.8 million, $2.4 million, and $3.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.